MARKSANSMarksans Pharma Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · India Ratings: AA- (Positive)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeMomentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹940 Cr | ₹144 Cr | 19.38% | 15.27% | ₹3.12 | 29.3x |
| Q1 FY2027 | ₹841 Cr | ₹159 Cr | 22.38% | 18.96% | ₹3.47 | 30.5x |
| Q4 FY2026 | ₹856 Cr | ₹149 Cr | 19.99% | 17.41% | ₹3.27 | 32.7x |
| Q3 FY2026 | ₹754 Cr | ₹114 Cr | 18.08% | 15.07% | ₹2.50 | 26.4x |
| Q2 FY2026 | ₹720 Cr | ₹99 Cr | 16.32% | 13.76% | ₹2.16 | 23.9x |
| Q1 FY2026 | ₹620 Cr | ₹58 Cr | 12.42% | 9.39% | ₹1.29 | 13.6x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.